Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann sold 5,184 shares of the firm’s stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $39.22, for a total transaction of $203,316.48. Following the completion of the sale, the executive vice president now directly owns 50,523 shares of the company’s stock, valued at approximately $1,981,512.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Mark Neumann also recently made the following trade(s):
- On Monday, January 11th, Mark Neumann sold 9,684 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $32.02, for a total value of $310,081.68.
Shares of NASDAQ:ITCI opened at $38.97 on Tuesday. The company has a 50 day moving average price of $34.88 and a two-hundred day moving average price of $27.56. The company has a market capitalization of $3.12 billion, a PE ratio of -12.10 and a beta of 1.50. Intra-Cellular Therapies, Inc. has a 52 week low of $10.94 and a 52 week high of $40.01.
Several equities research analysts have recently commented on the company. Zacks Investment Research cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 13th. BTIG Research cut their target price on shares of Intra-Cellular Therapies from $80.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. They noted that the move was a valuation call. Cantor Fitzgerald lifted their price target on shares of Intra-Cellular Therapies from $53.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 29th. The Goldman Sachs Group started coverage on shares of Intra-Cellular Therapies in a report on Thursday, December 10th. They issued a “buy” rating and a $38.00 price objective on the stock. Finally, Bank of America started coverage on shares of Intra-Cellular Therapies in a report on Tuesday, December 15th. They set a “buy” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $45.00.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Further Reading: Economic Reports
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.